Ben Khaled, Najib and Seidensticker, Max and Ricke, Jens and Mayerle, Julia and Oehrle, Bettina and Roessler, Daniel and Teupser, Daniel and Ehmer, Ursula and Bitzer, Michael and Waldschmidt, Dirk and Fuchs, Martin and Reuken, Philipp A. and Lange, Christian M. and Wege, Henning and Kandulski, Arne and Dechene, Alexander and Venerito, Marino and Berres, Marie-Luise and Luedde, Tom and Kubisch, Ilja and Reiter, Florian P. and De Toni, Enrico N. (2022) Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. FUTURE ONCOLOGY, 18 (12). pp. 1423-1435. ISSN 1479-6694, 1744-8301
Full text not available from this repository. (Request a copy)Abstract
The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab bevacizumab could be extended to the treatment of patients with intermediate-stage HCC in combination with transarterial chemoembolization (TACE). The authors describe the rationale and design of the DEMAND study. This investigator-initiated, multicenter, randomized phase 2 study is the first trial to evaluate the safety and efficacy of atezolizumab bevacizumab prior to or in combination with TACE in patients with intermediate-stage HCC. The primary end point is the 24-month survival rate; secondary end points include objective response rate, progression-free survival, safety and quality of life.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ENDOTHELIAL GROWTH-FACTOR; DOUBLE-BLIND; PHASE-III; ARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; PLUS BEVACIZUMAB; SORAFENIB; CELL; MULTICENTER; COMBINATION; atezolizumab; BCLC B; bevacizumab; hepatocellular carcinoma; immunotherapy; liver cancer; PD-L1; transarterial chemoembolization; VEGF |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2023 07:04 |
| Last Modified: | 14 Dec 2023 07:04 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58696 |
Actions (login required)
 |
View Item |
